A bibliographic review published in J. Med. Chem. provides an overview of the main druggable targets of SARS-CoV-2, as well as reported therapeutic compounds with activity against the virus
This novel vehicle has been used in a Phase IV vaccine for canine Leishmaniasis, it is designed free of toxic sequences and its industrial scaling process has already been carried out
The funding has been received by the projects LipidNET, with the participation of Dr. Pérez-Sala, and EPI-CATCH, which counts with Dr. Testillano among the proposers